phrykt

Tenaya Therapeutics, Inc. (TNYA): who owns it and who trades it

As of Nov 16, 2026, TNYA insiders reported 33 open-market sales worth $6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Column Group Iii-A, Lp (10% owner), with $3.5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Tenaya Therapeutics

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TNYA

101 funds and institutions reported TNYA shares worth $39.7M at the end of Q2 2026, about 25% of the company. The largest holder is Vanguard Capital Management LLC with 3.3%.

Funds and institutions (13F) 25%Everyone else 75%

10 largest owners, by share of the company

Vanguard Capital Management LLC3.3%
Millennium Management LLC3.0%
Citadel Advisors LLC2.1%
Renaissance Technologies LLC2.0%
BlackRock, Inc.1.8%
Empery Asset Management, LP1.8%
Marshall Wace, LLP1.6%
Gsa Capital Partners LLP1.2%
Burkehill Global Management, LP0.9%
Geode Capital Management, LLC0.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC7.10M3.27%$5.2M-16%
Millennium Management LLC6.43M2.96%$4.8M+18%
Citadel Advisors LLC4.57M2.10%$3.4M+9%
Renaissance Technologies LLC4.28M1.97%$3.2M+15%
BlackRock, Inc.4.01M1.85%$3M+8%
Empery Asset Management, LP3.86M1.78%$2.9M-10%
Marshall Wace, LLP3.50M1.61%$2.6M+29%
Gsa Capital Partners LLP2.67M1.23%$2M+149%
Burkehill Global Management, LP2.00M0.92%$1.5MNo change
Geode Capital Management, LLC1.83M0.85%$1.4M+18%
ADAR1 Capital Management, LLC1.56M0.72%$1.1M+3%
Raiffeisen Bank International AG1.20M0.55%$882K+20%
Euclidean Capital LLC1.02M0.47%$751KNo change
Vanguard Fiduciary Trust Co987,5050.46%$730K-3%
Mirador Capital Partners LP905,0970.42%$669K+2%
State Street Corp708,7210.33%$524KNo change
Squarepoint Ops LLC659,2470.30%$487K+89%
StepStone Group LP462,1630.21%$342KNo change
UBS Group AG456,5550.21%$337K-31%
Jane Street Group, LLC450,4350.21%$333K-62%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TNYA insiders reported $0 of open-market purchases and $6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$6M
33 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 17, 2026
Filed Aug 17, 2026

Purchases and sales by month

$5.9M$5.9MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 17, 2026Faraz AliCEOSale5,020$0.71$3.6KForm 4
Aug 17, 2026Faraz AliCEOSale7,406$0.71$5.3KForm 4
Aug 17, 2026Faraz AliCEOSale5,837$0.71$4.1KForm 4
Aug 17, 2026Faraz AliCEOSale3,969$0.71$2.8KForm 4
Aug 17, 2026Whittemore TingleyChief Medical OfficerSale1,637$0.71$1.2KForm 4
Aug 17, 2026Whittemore TingleyChief Medical OfficerSale1,871$0.71$1.3KForm 4
Aug 17, 2026Whittemore TingleyChief Medical OfficerSale2,279$0.71$1.6KForm 4
May 18, 2026Faraz AliCEOSale3,390$0.79$2.7KForm 4
May 18, 2026Whittemore TingleyChief Medical OfficerSale3,121$0.79$2.5KForm 4
May 18, 2026Tomohiro HigaVice presidentSale1,485$0.79$1.2KForm 4
Feb 25, 2026TCG Opportunity III GP, LLC +710% ownerSale1.65M$0.56$924KForm 4
Feb 25, 2026TCG Opportunity III GP, LLC +710% ownerSale1.86M$0.56$1MForm 4
Feb 24, 2026TCG Opportunity III GP, LLC +710% ownerSale349,212$0.62$217KForm 4
Feb 24, 2026TCG Opportunity III GP, LLC +710% ownerSale309,228$0.62$192KForm 4
Feb 23, 2026Column Group Iii-A, Lp +710% ownerSale162,291$0.60$97.4KForm 4
Feb 23, 2026Column Group Iii-A, Lp +710% ownerSale143,709$0.60$86.2KForm 4
Feb 20, 2026Column Group Iii-A, Lp +710% ownerSale277,769$0.61$169KForm 4
Feb 20, 2026Column Group Iii-A, Lp +710% ownerSale245,965$0.61$150KForm 4
Feb 17, 2026Tomohiro HigaVice presidentSale836$0.64$535Form 4
Feb 17, 2026Tomohiro HigaVice presidentSale2,022$0.64$1.3KForm 4
Feb 17, 2026Tomohiro HigaVice presidentSale611$0.64$391Form 4
Feb 17, 2026Faraz AliCEOSale5,032$0.64$3.2KForm 4
Feb 17, 2026Faraz AliCEOSale5,851$0.64$3.7KForm 4
Feb 17, 2026Faraz AliCEOSale3,979$0.64$2.5KForm 4
Feb 17, 2026Whittemore TingleyChief Medical OfficerSale1,642$0.64$1.1KForm 4
Feb 17, 2026Whittemore TingleyChief Medical OfficerSale1,876$0.64$1.2KForm 4
Feb 11, 2026Column Group Iii-A, Lp +710% ownerSale2.15M$0.68$1.5MForm 4
Feb 11, 2026Column Group Iii-A, Lp +710% ownerSale1.91M$0.68$1.3MForm 4
Feb 10, 2026Column Group Iii-A, Lp +710% ownerSale161,422$0.82$132KForm 4
Feb 10, 2026Column Group Iii-A, Lp +710% ownerSale182,295$0.82$149KForm 4
Nov 17, 2025Tomohiro HigaVice presidentSale1,367$1.33$1.8KForm 4
Nov 17, 2025Whittemore TingleyChief Medical OfficerSale2,877$1.33$3.8KForm 4
Nov 17, 2025Faraz AliCEOSale3,126$1.33$4.2KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Column Group Iii-A, Lp10% owner–$3.5MFeb 23, 2026
TCG Opportunity III GP, LLC10% owner–$2.4MFeb 25, 2026
Faraz AliChief Executive Officer, Director–$32.1KAug 17, 2026
Whittemore TingleyChief Medical Officer–$12.7KAug 17, 2026
Tomohiro HigaSVP, Finance–$5.2KMay 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TNYA short interest

High short interest. 10.3% of TNYA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 19%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 23.41M TNYA shares were sold short, 10.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 2.69M shares, buying them all back would take about 8.7 trading days (days to cover).

Shares short, % of all shares

10.3%May 15Oct 3014.1%

Days to cover

8.7May 15Oct 3015.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202623.41M10.27%+4%2.69M8.7
Oct 15, 202622.52M10.04%-2%4.86M4.6
Sep 30, 202622.92M10.22%+6%3.04M7.5
Sep 15, 202621.64M9.65%+4%1.70M12.8
Aug 31, 202620.77M9.26%-2%1.96M10.6
Aug 14, 202621.10M9.41%-4%2.11M10.0
Jul 31, 202621.99M9.81%-12%1.60M13.7
Jul 15, 202624.92M11.48%-5%3.36M7.4
Jun 30, 202626.23M12.09%-8%2.02M13.0
Jun 15, 202628.66M13.21%-2%3.41M8.4
May 29, 202629.30M13.50%+2%3.09M9.5
May 15, 202628.75M13.25%+3%6.52M4.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Tenaya Therapeutics company events

Tenaya Therapeutics filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 5, 2026ResultsReleased financial results. Filing
  3. Jul 2, 2026AgreementEnded an important agreement. Filing
  4. Jun 29, 2026LeadershipTenaya Therapeutics, Inc. announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026, and in such capacity, will serve as the Company’s Principal Financial Officer and Principal Accounting Officer beginning on the Commencement Date. Filing
  5. May 29, 2026LeadershipTenaya Therapeutics, Inc. amended and restated its 2021 Equity Incentive Plan, effective as of May 27, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
  6. May 6, 2026ResultsReleased financial results. Filing
  7. Mar 11, 2026ResultsReleased financial results. Filing
  8. Mar 5, 2026AgreementTenaya Therapeutics, Inc. entered into a collaboration agreement with Alnylam Pharmaceuticals, Inc., pursuant to which the parties agreed to a research collaboration to discover and validate novel gene targets for the potential treatment of cardiovascular disease. Filing
  9. Jan 30, 2026ListingTenaya Therapeutics, Inc. received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of shares of the Company’s common stock for the 30 consecutive business day period between December 12, 2025, through January 27, 2026… Filing
  10. Jan 2, 2026LeadershipIn connection with his retirement, David Goeddel submitted his resignation from the board of directors of Tenaya Therapeutics, Inc. and as a member of all committees of the Board, effective January 26, 2026. Filing
  11. Dec 12, 2025AgreementTenaya Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co., as representatives of the underwriters listed therein, relating to the issuance and sale in a firm commitment underwritten public offering of 50,000,000 units, at a public offering… Filing
  12. Dec 11, 2025AnnouncementFollowing proactive correspondence with the FDA relating to future development plans for TN-201, on November 7, 2025, the Company announced that the FDA placed MyPEAK-1 on clinical hold requesting an amendment to the protocol primarily to standardize activities related to patient monitoring and… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Tenaya Therapeutics financials

Famous investors that hold TNYA

3 of the 50 well-known investors we track reported holding TNYA in their latest 13F filing. The largest position is Israel Englander's, worth $6.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202610.24M$6.2M0.0%+59%
Ken Griffin · Citadel AdvisorsQ3 20264.51M$2.7M0.0%-1%
Jim Simons · Renaissance TechnologiesQ3 20262.96M$1.8M0.0%-31%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TNYA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026The Column Group Opportunity III, LP13D/A21.6%
Nov 16, 2026The Column Group Opportunity III, LP13D/A21.6%

Questions about Tenaya Therapeutics, Inc. (TNYA) stock

Who owns the most TNYA stock?

The largest reported owner of Tenaya Therapeutics, Inc. (TNYA) is Vanguard Capital Management LLC, with 3.3% of the company. In total, 101 funds and institutions reported holding TNYA at the end of Q2 2026, together about 25% of the shares. See the largest owners.

Are TNYA insiders buying or selling?

In the last 12 months, TNYA insiders reported no open-market purchases and 33 sales worth $6M. The latest trade was on Aug 17, 2026. See every trade.

What is the short interest in TNYA?

As of Oct 30, 2026, 23.41M TNYA shares were sold short, 10.3% of the shares outstanding, up 4.0% from the report before. At the average daily volume of 2.69M shares, buying them all back would take about 8.7 trading days (days to cover). See the history.

Which famous investors hold TNYA?

3 of the 50 well-known investors we track reported TNYA in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $6.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.